Astrazeneca PLC (AZN) Receives “Neutral” Rating from JPMorgan Chase & Co.
Astrazeneca PLC (NYSE:AZN)‘s stock had its “neutral” rating reiterated by JPMorgan Chase & Co. in a research report issued on Friday.
Other analysts have also issued research reports about the stock. Cantor Fitzgerald restated a “buy” rating on shares of Astrazeneca PLC in a research note on Thursday. Shore Capital restated a “hold” rating on shares of Astrazeneca PLC in a research note on Thursday. Bank of America Corp. restated a “buy” rating and set a $41.37 price target on shares of Astrazeneca PLC in a research note on Thursday. Deutsche Bank AG restated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday. Finally, Beaufort Securities restated a “hold” rating on shares of Astrazeneca PLC in a research note on Friday. Three analysts have rated the stock with a sell rating, eight have given a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $37.61.
Astrazeneca PLC (NYSE:AZN) opened at 27.68 on Friday. The company has a market capitalization of $70.03 billion, a price-to-earnings ratio of 31.63 and a beta of 0.83. The stock has a 50 day moving average of $30.74 and a 200 day moving average of $30.85. Astrazeneca PLC has a 12 month low of $26.97 and a 12 month high of $35.04.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, November 10th. The company reported $1.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.58. The business earned $5.70 billion during the quarter, compared to analyst estimates of $5.95 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. Astrazeneca PLC’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.03 EPS. Equities analysts anticipate that Astrazeneca PLC will post $2.99 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in AZN. RDL Financial Inc. bought a new position in Astrazeneca PLC during the second quarter valued at $532,000. Ngam Advisors L.P. boosted its position in Astrazeneca PLC by 72.4% in the second quarter. Ngam Advisors L.P. now owns 440,868 shares of the company’s stock valued at $13,310,000 after buying an additional 185,089 shares during the period. Boyer & Corporon Wealth Management LLC boosted its position in Astrazeneca PLC by 1.6% in the second quarter. Boyer & Corporon Wealth Management LLC now owns 28,222 shares of the company’s stock valued at $852,000 after buying an additional 434 shares during the period. Becker Capital Management Inc. bought a new position in Astrazeneca PLC during the second quarter valued at $35,701,000. Finally, O Shaughnessy Asset Management LLC bought a new position in Astrazeneca PLC during the second quarter valued at $4,535,000. Hedge funds and other institutional investors own 11.35% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.